Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer

R Baillie¹, J Carlile¹, N Pendleton², A M Schor¹

¹ Unit of Cell and Molecular Biology, Dental School, University of Dundee, Park Place, Dundee DD1 4HR, UK
² Department of Geriatric Medicine, University of Manchester, Hope Hospital, Salford M6 8HD, UK

Correspondence to:
Dr Schor a.m.schor{at}dundee.ac.uk

Aims—High expression of the angiogenic factor vascular endothelial growth factor (VEGF) in tumours has been found to be associated with poor prognosis in some studies, but not in others. The aims of this study were to determine the prognostic value of VEGF in operable non-small cell lung cancer (NSCLC) and its possible association with vascularity.

Methods—Sections from 81 NSCLC archival specimens were stained with antibodies to von Willebrand factor (vWF) and VEGF. Vascularity was measured by the average density of vWF positive vessels. VEGF expression in tumour cells was assessed by consensus of two independent observers according to three indices, namely: (1) percentage of area stained, (2) intensity of staining, and (3) final score (product of area and intensity).

Results—VEGF immunoreactivity was present in all tumours and adjacent normal lung tissue. None of the three VEGF indices was associated with vascularity or the clinical parameters examined. Mean survival times were shorter in patients with high VEGF expression, but the difference was not significant. This applied to the full cohort of patients, or when analysed separately according to tumour type or stage. However, high VEGF expression was associated with poor survival in patients with high vascularity (p = 0.02). VEGF had no discriminant value among patients with low vascularity. Vascularity had no prognostic value, except for late stage patients (UICC stages II and IIIa combined; n = 36), where high vascularity was associated with longer survival (p = 0.01).

Conclusions—VEGF on its own has no prognostic value in NSCLC, but may become a useful indicator when combined with vascularity. VEGF may play a physiological role in the normal lung.

Key Words: non-small cell lung cancer • vascular endothelial growth factor • vascularity • prognosis

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Ozbudak, I. H., Ozbilim, G., Kucukosmanoglu, I., Dertsiz, L., Demircan, A. (2009). Vascular Endothelial Growth Factor Expression and Neovascularization in Non--Small Cell Lung Carcinoma. INT J SURG PATHOL 17: 390-395 [Abstract]  
• Zhu, C-Q, Shih, W, Ling, C-H, Tsao, M-S (2006). Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.. J. Clin. Pathol. 59: 790-800 [Abstract] [Full Text]  
• Shikada, Y., Yonemitsu, Y., Koga, T., Onimaru, M., Nakano, T., Okano, S., Sata, S., Nakagawa, K., Yoshino, I., Maehara, Y., Sueishi, K. (2005). Platelet-Derived Growth Factor-AA Is an Essential and Autocrine Regulator of Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Carcinomas. Cancer Res. 65: 7241-7248 [Abstract] [Full Text]  
• Wong, S. C. C., Lo, E. S. F., Lee, K. C., Chan, J. K. C., Hsiao, W. L. W. (2004). Prognostic and Diagnostic Significance of {beta}-Catenin Nuclear Immunostaining in Colorectal Cancer. Clin. Cancer Res. 10: 1401-1408 [Abstract] [Full Text]  
• Poleri, C., Morero, J. L., Nieva, B., Vazquez, M. F., Rodriguez, C., de Titto, E., Rosenberg, M. (2003). Risk of Recurrence in Patients With Surgically Resected Stage I Non-small Cell Lung Carcinoma: Histopathologic and Immunohistochemical Analysis. Chest 123: 1858-1867 [Abstract] [Full Text]  
• Spiro, S. G., Porter, J. C. (2002). Lung Cancer--Where Are We Today?: Current Advances in Staging and Nonsurgical Treatment. Am. J. Respir. Crit. Care Med. 166: 1166-1196 [Abstract] [Full Text]  
• Laack, E., Kohler, A., Kugler, C., Dierlamm, T., Knuffmann, C., Vohwinkel, G., Niestroy, A., Dahlmann, N., Peters, A., Berger, J., Fiedler, W., Hossfeld, D. K. (2002). Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 13: 1550-1557 [Abstract] [Full Text]  
• de Bont, E. S. J. M., Fidler, V., Meeuwsen, T., Scherpen, F., Hahlen, K., Kamps, W. A. (2002). Vascular Endothelial Growth Factor Secretion Is an Independent Prognostic Factor for Relapse-free Survival in Pediatric Acute Myeloid Leukemia Patients. Clin. Cancer Res. 8: 2856-2861 [Abstract] [Full Text]  
• Brock, C.S., Lee, S.M. (2002). Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer. Eur Respir J 19: 557-570 [Abstract] [Full Text]